Safety and Efficacy of pALG in Conditioning Regimen for HLA-Matched Sibling HSCT in Patients With SAA or Hematological Malignancies ( pALG-MSDHSCT )
Key facts
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 60 people, planned
- Starts
- 30 Nov 2026
- Expected to end
- 31 Aug 2028
- Type of study
- Observational
- Treatments tested
- Exploration of porcine anti-human T-lymphocyte immunoglobulin (p-ALG)
- Record updated
- 17 November 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- age: no age limit for severe aplastic anemia type I or II, patient or donor age>40 years for hematologic malignancies
- gender: no gender limit
- sibling identical hematopoietic stem cell transplantation
- fair general status, ECOG score <2 points
- no age limit for severe aplastic anemia, no gender limit; patient or donor age>40 years for hematologic malignancies
Who cannot take part
- Prior hematopoietic stem cell transplantation;
- uncontrolled viral, bacterial and fungal infections (disease progression during antifungal therapy)
- psychiatric disorders or other medical conditions unable to comply with study treatment and monitoring requirements
- known seropositive for HIV, active hepatitis B, active hepatitis C virus, or syphilis
- history of tumor and treatment for any tumor within the past 3 years
- Active heart disease, defined as one or more of the following: ① Long QTc syndrome or QTc interval>480ms;② Complete left bundle branch block, degree II or III atrioventricular block;③ History of arrhythmia requiring medication or severe clinical symptoms;④ American New York Heart Association classification ≥II; ④ Left ventricular ejection fraction less than 50%; History of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, history of clinically serious pericardial disease, or ECG evidence of acute ischemic or active conduction system abnormalities within 6 months prior to enrollment
- pregnant and lactating patients or patients unable to use appropriate contraception during treatment
- Subjects considered unsuitable for enrollment by the investigator
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Severe aplastic anemia or hematologic malignancies
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a single-arm clinical study designed to evaluate the safety and efficacy of p-ALG in HLA sibling identical Hematopoietic stem cell transplantation( HSCT) conditioning regimens for severe aplastic anemia (SAA)/hematologic malignancies in patients diagnosed with hematologic malignancies or sSAA requiring allogeneic HSCT from our center. Graft anti-host disease (GVHD) is the most common and severe complication of allogeneic HSCT, which significantly affects survival and quality of life. Even among recipients of HLA-identical sibling HSCT (MSD-HSCT), the incidence of acute GVHD( aGVHD) and chronic GVHD (cGVHD) reaches 40-50% and 30-70%, respectively.
The group in the trial
- p-ALG cohort
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.
Treatment: Exploration of porcine anti-human T-lymphocyte immunoglobulin (p-ALG)
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Efficacy of Anti-human T-cell Porcine Immunoglobulin in Conditioning Regimens for HLA Sibling Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia (SAA)/Hematological Malignancies
- Criteria questions
- Built from NCT07943039, who can take part
- Record updated
- 17 November 2026